We welcomed a steady stream of customers and prospects from around the world to our booth over three days. Showcasing a wide range of products from our Hemostasis and Whole Blood Hemostasis product lines, the booth featured:
- ACL TOP Family 50 Series Testing Systems (350, 550,750)
- HemoCell Specialized Lab Automation
- HemoHub Intelligent Data Manager
- ACL AcuStar
- HemosIL assays
- ProDx
- AccuTrak 2.0
- ROTEM sigma
- VerifyNow
- GEM Hemochron 100
Additionally, with its expanded controlled distribution this year, the new ACL TOP 970 CL Testing System was also on display, with great interest and enthusiasm from attendees.
Presentation Theater
On Sunday, June 25, Werfen hosted a Presentation Theater titled “Rapid HIT Testing: Are Two Tests Better Than One?” featuring Dr. Ted Warkentin, Professor at McMaster University and Hematologist at Hamilton General Hospital, Ontario, Canada. Dr. Warkentin discussed the ‘clinical-pathological’ anti-platelet factor 4 disorder, heparin-induced thrombocytopenia (HIT), and the role of rapid, on-demand HIT antibody testing. Yielding a full, standing-room-only audience, the Presentation Theater was very well attended with 110 participants from over 30 countries, and moderated by Dr. Annie Winkler, Werfen’s VP of Reagent Development and Medical Affairs. The event was compelling and supportive of the use of our HemosIL HIT-IgG (PF4-H) and HIT-Ab (PF4-H) assays. Following the presentation, Dr Warkentin responded to many questions from the highly engaged audience. The recorded presentation will now be leveraged as part of the Hemostasis Heparin Management Symposium, to be held on October 24. Following the Symposium, the recording will then be made available for broader, on-demand access and viewing on Werfen Academy.
Luca Rodighiero, Marketing Director EEMEA